ABSTRACT-Introduction: Sepsis-induced metabolic disturbances include hyperlactatemia, disruption of glycolysis, protein catabolism, and altered fatty acid metabolism. It may also lower serum L-carnitine that supports the use of L-carnitine supplementation as a treatment to ameliorate several of these metabolic consequences. Methods: To further understand the association between L-carnitine-induced changes in serum acylcarnitines, fatty acid metabolism and survival, serum samples from (T0), 12 hfollowing completion (T24) of L-carnitine (n ¼ 16) or placebo (n ¼ 15) administration, and 48 h (T48) after enrollment from patients with septic shock enrolled in a randomized control trial were assayed for acylcarnitines, free fatty acids, and insulin. Data were analyzed comparing 1-year survivors and nonsurvivors within treatment groups. Results: Mortality was 8 of 16 (50%) and 12 of 15 (80%) at 1 year for L-carnitine and placebo-treated patients, respectively. Free carnitine, C2, C3, and C8 acylcarnitines were higher among nonsurvivors at enrollment. LCarnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors. Several fatty acids followed a similar, though less consistent pattern. Glucose, lactate, and insulin levels did not differ based on survival or treatment arm. Conclusions: In human patients with septic shock, L-Carnitine supplementation increases a broad range of acylcarnitine concentrations that persist after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome. Nonsurvivors demonstrate a distinct metabolic response to L-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment.
INTRODUCTION
Despite advances in early recognition and care of patients with severe sepsis, patients with septic shock continue to demonstrate a mortality rate of approximately 40% (1) . Clinical trials targeting the condition have continued to yield disappointing results, and specific pharmacologic therapies for the condition are lacking. Traditionally, many of these trials target the well-known pathophysiologic manifestations of the sepsis syndrome, namely, the inflammatory and coagulation cascades.
In addition to an inflammatory disease, however, sepsis might be considered and approached as an acute metabolic illness. Sepsis induces a series of physiologic changes, including increased glycolysis, protein catabolism, lipolysis, and neuroendocrine activation, resulting in a number of metabolic changes including hyperglycemia, hyperlactatemia, and alternations in circulating amino acids, fatty acids (FA), and lipoproteins (2) . In addition to these effects, several lines of evidence suggest specific changes in metabolic pathways involving L-carnitine. Sepsis induces a relative L-carnitine deficiency, with decreased muscle and plasma levels and increased urinary excretion (3) . In addition, the activities of carnitine-dependent enzymes such as carnitine acyl and palmitoyltransferases are altered following lipopolysaccharide injection (4) . Carnitine is also necessary for the conjugation and transfer of long-chain acyl CoA into the mitochondria for betaoxidation of FA. Together, these data suggest a potentially important role for carnitine in the metabolic response in sepsis.
The advent of new, high-throughput metabolomics platforms has reinvigorated interest in the metabolic response of patients to sepsis. Previous studies have demonstrated systematic shifts in energy metabolism using such platforms and raised interesting hypotheses regarding novel therapeutic targets to improve energy metabolism and mitigate organ dysfunction in patients with sepsis (5-9). More recently, a large observational cohort study of patients found a broad dysregulation of acylcarnitine levels among sepsis nonsurvivors using untargeted metabolomics, suggesting potential disruptions in FA-related metabolic pathways (9) . We previously completed a phase I pilot randomized control trial testing the hypothesis that a single bolus and 12-h infusion of L-carnitine is safe and demonstrates preliminary efficacy (10) . Although not powered to detect a mortality benefit, a statistically significant reduction in 28-day mortality was observed among patients treated with L-carnitine, and a multicenter phase II clinical trial is currently nearing completion (NC01665092).
Using patient samples from the phase I pilot study, we previously demonstrated that carnitine-treated 1-year sepsis survivors had a distinct metabolic profile compared with nonsurvivors using quantitative proton nuclear magnetic resonance ( 1 H-NMR) metabolomics (11) . Specifically, we observed multiple L-carnitine-induced metabolic changes, and most interestingly found nearly all of the clinical benefit in the intervention group could be attributed to a group of L-carnitine ''users'' that could be identified based on their pretreatment metabolome. One of the most prominent findings of this study was that Lcarnitine levels following supplementation was highly predictive of 28-day and 1-year survival, leading us to question what impact L-carnitine accumulation might have on acylcarnitines, FA, and glycolysis. We hypothesized that L-carnitine treatment would differentially affect systemic acylcarnitines and provide additional insights into the impact of L-carnitine treatment on the metabolic response to sepsis.
MATERIALS AND METHODS

Description of the clinical trial
This is a secondary analysis of serum samples from patients enrolled in a FDA-regulated (IND #107,086), IRB-approved, clinical trial of L-carnitine administration registered on clinicaltrial.gov (NCT01193777), which has previously been published (10) . All patients or their surrogates gave informed consent before enrollment. Inclusion criteria included two or more systemic inflammatory response syndrome (SIRS) criteria, confirmed or suspected infection demonstrated by administration of intravenous antibiotics, a sequential organ failure assessment (SOFA) (12) score of at least 5, continuous administration of vasopressors for at least 4 h with a cumulative vasopressor index (13) of at least 3 following volume resuscitation, and enrollment within 16 h of the recognition of sepsis. Abbreviated exclusion criteria included age less than 18 years, any primary diagnosis other than sepsis, a preexisting do-notresuscitate order, a history of seizures (due to the risk of L-carnitine in lowering the seizure threshold), or known inborn error of metabolism. Patients were randomized in a double-blind fashion to receive either L-carnitine (single dose of 12 g delivered as a 4 g bolus followed by an 8 g infusion diluted in 1 L of normal saline and delivered over the subsequent 12 h) or an equivalent volume of normal saline. Clinical variables were recorded prospectively at the bedside and were used in conjunction with prospectively ordered clinical laboratory tests at the same time points to calculate SOFA scores.
Blood draws and processing
Blood samples were collected via an existing intravenous or arterial catheter before dosing (T0) and 12 h after the completion of the infusion (T24; AE4 h) and then again 24 h later (T48; AE4 h) as previously described (11) . Resulting serum was aliquoted into 500 mL samples and stored at (-80-C) until the time of assay.
H-NMR metabolomics
We used existing 1 H-NMR metabolomics data, specifically the concentration values of lactate and glucose, that were generated from technical replicates of the samples used for this study. We elected to use these rather than clinical measurements to ensure consistency in interpreting the data, as different sample collection techniques, blood processing, use of whole blood versus serum, and use of point-of-care devices could introduce bias. These methods and results have been previously reported (11) , and these data can be found at http:// www.metabolomicsworkbench.org/.
Measurement of acylcarnitines by liquid chromatography-mass spectroscopy: To prepare serum for acylcarnitine analysis, extraction solvent consisting of a 1:1:1 mixture of methanol:acetonitrile:acetone plus a 1:200 dilution of a stock mixture of stable-isotope labeled acylcarnitine standards dissolved according to manufacturer instructions (NSK-B; Cambridge Isotope Laboratories) was prepared. Serum was extracted by the addition of 200 mL extraction solvent to 50 mL serum in a microcentrifuge tube, followed by vortexing for 10 s. After 5 min on ice, the samples were centrifuged (15,000 Â g, 5 min) and 200 mL of supernatant was transferred to a clean tube and dried with a gentle stream of nitrogen gas. Dried samples were reconstituted in 50 mL of a 9:1 mixture of water:methanol, which was transferred to autosampler vials with low-volume inserts for analysis. Acylcarnitine species were then analyzed without derivatization by RPLC-MS/MS using an Agilent 1200 LC coupled to an Agilent 6410 tandem quadrupole mass spectrometer (Santa Clara, Calif). Absolute quantitation was performed for acylcarnitine species with exactmatching stable isotope internal standards (L-carnitine, C2, C3, C4, C5, C8, C14, C16) by multiplying the ratio of the unlabeled/labeled peak area by the known concentration of the original plasma sample. Other acylcarnitine species were assayed using relative quantitation by peak area. Additional analytical details about the assay can be found in the online supplement, http://links. lww.com/SHK/A643.
Insulin measurements
Serum samples were assayed for insulin concentration using a doubleantibody radioimmunoassay that uses a 125I-Human insulin tracer (Linco Research), a guinea pig antiporcine insulin first antibody (MDRTC, 68.5% cross-reaction to human proinsulin), and a goat antiguinea pig gamma globulin (Antibodies Inc.)-PEG second antibody and standardized against the Human Insulin International Reference Preparation (NIBSC) as previously described (14) .
Free FA measurements
The protocol of lipid extraction was adapted from a published method (15) with slight modification as follows: total lipids were extracted using a mixture of chloroform-methanol (1:2) containing 0.01% butylated hydroxytoluene with known amount of heptadecanoic acid (C17:0) as an internal standard, followed by further treatment with chloroform and NaCl (0.9%) for phase separation. The organic layer containing lipids was separated, FA was isolated using silica gel thin-layer chromatography, subjected to transmethylation with BF 3 -methanol (16) , and analyzed by gas chromatography (GC). Analysis was performed on an Agilent GC model 6890N using Chemstation software. The GC column was an Agilent HP 88, 30 m, 0.25 mm I.D. and 0.20 mm film thickness. Hydrogen was used as a carrier gas as well as for the FID detector and nitrogen was used as a makeup gas. Analyses were carried out with a temperature program of 1258C to 2208C. The coefficient of variation for GC analyses was within 2.5% to 3.6%.
Data analysis: Clinical data were summarized using simple descriptive statistics, and differences between groups were determined using chi-square, Fisher exact, Student t test, or a Mann-Whitney U test, as appropriate. For the purposes of this analysis, patients were categorized by 1-year mortality and treatment arm. As the primary focus of the work was to determine differences in carnitine and acylcarnitine concentrations between carnitine or placebo-treated patients based on survival, we compared data at each time point using a MannWhitney U test. Resulting P values for carnitine, acylcarnitine, and FA concentration comparisons were corrected for multiple comparisons using false discovery rate (17) and are reported as q values. All figures were constructed, and statistical two-sided tests were performed in PRISM (version 7.0c for Mac; GraphPad Software, Inc., La Jolla, Calif); P values 0.05 were considered significant.
RESULTS
We enrolled 31 patients in the trial, 16 in the L-carnitine arm and 15 in the placebo arm. Patient demographics and clinical characteristics stratified by treatment allocation and survival can be found in Tables 1 and 2 , respectively. Overall, patients enrolled in the study were critically ill with a median (IQR) SOFA score of 12 (6, 14) , all patients required vasopressor support, and the cohort had an intubation rate of 71%. Although there were disproportionately fewer females in the study (n ¼ 10 vs. 21 males), there was only one female survivor at 1 year (Table 1) . As previously noted (10), patients enrolled into the treatment arm had significantly higher SOFA scores (primarily related to the respiratory component and a higher rate of intubation, data not shown), though the treatment arms were otherwise well matched. One-year mortality was 80% and 50% in the placebo and treatment arms, respectively, with a trend toward improved survival (P ¼ 0.06), suggesting potential clinical efficacy of L-carnitine that is undergoing further testing in an ongoing clinical trial (NC01665092) (10, 18) .
At enrollment, there were no significant differences in the levels of free or any acylcarnitine levels when comparing treatment arms. Further visual inspection of free and acylcarnitine levels in placebo-treated patients demonstrated relative stability over 48 h, regardless of patient survival (Fig. 1, A-H,  right) , and no measured difference was statistically significant. On the contrary, among patients treated with L-carnitine, levels of all measured carnitine species (C0, C2, C3, C4, C5, C6, and C8), with the exception of C16, were higher in carnitine-treated nonsurvivors compared with survivors at T0, T24, and T48 (Fig. 1, A-H, left) . Nonsurvivors demonstrated a global, more profound increase in free carnitine and acylcarnitines in response to supplementation as compared with survivors, an effect that was most notable 12 h following completion of the infusion (T24) but still observable 36 h after cessation (T48). Other acylcarnitines followed similar temporal trends (see Figure E1 in the online supplement, http://links.lww.com/ SHK/A644). Notably, these differences could not be explained by differences in renal function as assessed by serum creatinine, which neither differed significantly between nonsurvivors and survivors in the entire study [1.7 (1.5-2.3) and 2.1 (1.4-3.4) mg/dL; P ¼ 0.49] nor in the subset of patients treated with L-carnitine [2.1 (1.6-2.6) and 1.8 (1.5-2.8) mg/dL; P ¼ 0.49]. A representative chromatogram of acylcarnitines is shown in Figure E2 in the online supplement, http://links.lww.com/SHK/ A645.
Total free FA did not differ significantly between survivors and nonsurvivors before enrollment (50 (30-97) vs. 65 (55-102) nmol/100 mL, P ¼ 0.15). Levels of the various measured FA also did not differ significantly between treatment groups before initiation of treatment with the exception of 22:0 that was higher in L-carnitine-treated patients [0.22 (0.13-0.28) vs. 0.14 (0.09-0.2)]. Similar to the trend observed in the acylcarnitines, levels of the various FA tended to be higher in the Lcarnitine-treated survivors versus nonsurvivors (Fig. 2) , though only 20:0 and 22:0 met statistical significance (Fig. 2, K and Q) at T0. There were no significant differences in FA levels in placebo-treated survivors compared with nonsurvivors before enrollment. Following treatment, the levels of 18:3 (n-6), 20:5, 22:0, and 24:1 (Fig. 2, J , P, and W) trended up in L-carnitinetreated nonsurvivors compared with survivors. There were no significant differences in FA concentrations between survivors and nonsurvivors in the placebo groups although 22:1 trended higher ( 2) vs. 28.2 (13.6-64.6), P ¼ 0.01 mU/mL]. Finally, to further evaluate the relationship between potential markers of altered glycolysis in response to L-carnitine supplementation, we analyzed glucose, lactate, lactate:glucose ratio, and insulin levels over the same time points. Carnitine-treated nonsurvivors had lower pretreatment insulin levels than carnitine-treated survivors [7.8 (4.4-19.5) vs. 49.6 (11.8-94.6) mU/mL; P ¼ 0.04] but otherwise we found no significant differences in glucose, lactate, lactate:-glucose ratio, or insulin levels when analyzing patients based on survival and treatment (data not shown). However, these data were limited by significant individual variability among patients and incomplete clinical data related to fasting status or feeding regimens and supplemental insulin administration.
DISCUSSION
In this study, we report the impact of L-carnitine treatment on serum concentrations of acylcarnitines and FA in patients with septic shock, which we have previously reported to have potentially beneficial effects on patient outcomes. Here we show that intravenous L-carnitine supplementation to patients with septic shock leads to an immediate and sustained increased in short-, medium-, and long-chain acylcarnitines that persist for at least 36 h following completion of intravenous infusion. These data demonstrate that this method of supplementation does, indeed, result in cellular uptake and substrate utilization through the formation of acylcarnitines supporting the biologic plausibility of the treatment. These increases in acylcarnitine concentrations are not unexpected as this has previously been reported with carnitine supplementation (19) (20) (21) . Rather, the primary finding of this study is that carnitine-treated septic shock nonsurvivors had substantially higher concentrations of carnitine and acylcarnitines following L-carnitine administration compared with survivors. This finding cannot simply be explained by differences in endogenous serum carnitine at T0 because the median difference in carnitine concentration at T24 was much greater [i.e., 485 (IQR: 401-998) mM; see Fig. 2A ] than the difference in the median concentration at T0 (17 (IQR: 11-25) mM; see Fig. 1A ) between survivors and nonsurvivors FIG. 1. Temporal changes in serum concentrations of carnitine and acylcarnitines highlight metabolic phenotypes of 1-year septic shock survival. Carnitine supplementation resulted in higher (A) carnitine, (B) acetylcarnitine, (C) C3, (D) C4, (E) C5, (F) C8, (G) C14, and a trend in higher (H) C16 between survivors and nonsurvivors. These patterns were distinct from placebo-treated patients for which survivors and nonsurvivors had similar trends in levels of carnitine and acylcarntines. Data are median and IQR. (22) . It also cannot be explained by differences in renal function between the two groups. As L-carnitine is renally cleared, we might have expected the differences between L-carnitinetreated survivors and nonsurvivors to reflect differences in renal function, though similar creatinine levels at enrollment suggest against this explanation. Orally ingested L-carnitine is metabolized by gut flora that results in the generation of trimethylamine (23) . However, IV administration bypasses this mechanism and to the best of our knowledge there are no other degradative or metabolic pathways of carnitine that could explain these differences; carnitine is primarily excreted unchanged in the urine (24) . Alternatively, we contend that these data imply that there is a differential metabolic response to carnitine supplementation in septic shock that reflects the underlying the metabolic dysfunction of sepsis that could be used to inform subsequent experimental design, either clinical or preclinical. This has been substantiated by our previous work that showed that L-carnitine-treated responders have a unique metabolic profile (11) . Finally, the uptake and retention of acylcarnitines in tissues and organs, and its role in those compartments, was not assessed given the limitations of clinical research, and remains an open area for future investigations.
Sepsis induces all manner of metabolic disturbances that have been long recognized, including evidence of alterations in glycolysis (most notably hyperglycemia and hyperlactatemia, but also including alterations in pyruvate), protein catabolism, and FA metabolism (25) . Most recently, large-scale unbiased metabolomics approaches have compared patients with sepsis of varying severity that identified acylarnitines as predictive of patient outcome (5, 9) . In these studies, patients did not receive supplemental carnitine. Here, we show that administration of Lcarnitine provokes the observed metabolic phenotype because placebo-treated patients had no differences in their levels of acylcarnitines at enrollment. It is worthwhile to note that we did not observe a significant effect of L-carnitine treatment on various metabolic markers related to glycolysis, namely, glucose, lactate, and insulin. This is relevant, as it might be hypothesized that L-carnitine treatment affects these pathways via its indirect effects on pyruvate dehydrogenase activity through the shuttling of excess acety L-coA out of the inner mitochondrial space. Although we did not observe a significant effect on glycolysis based on our simple measurements, we likewise cannot completely rule out such an effect due to the large interpatient variability in the levels that we observed. Rather, this pathway would require a more tightly controlled clinical study in a larger cohort to definitely interrogate the potential effects of L-carnitine on glycolysis.
Given the absence of differences in long-chain FA (<C22) concentrations between carnitine-treated survivors and nonsurvivors, which serve as the substrates of acylcarnitines, we conclude that the variance in carnitine-induced increases in acylcarnitines between these patients is attributable to the disposition of carnitine (21) . Although the mechanism of carnitine disposition was not specifically assessed in this study, it is possible that the lower plasma carnitine and acylcarnitine levels in survivors reflect improved uptake and maintenance of carnitine in the tissues, which could include urinary excretion of carnitine and acylcarnitines, where it would have potential to enhance lipid metabolism and help ameliorate the metabolic crisis associated with sepsis. We acknowledge that there was greater variability in FA concentrations across patients that may reflect a range of fasting and fed states (26) . Given this and our small sample size, it is difficult to detect a consistent pattern of FA levels that may distinguish survivors and nonsurvivors. Nevertheless, the explanation for the broad range of carnitine and acylcarnitine concentrations following a single intravenous dose of carnitine, which, to the best of our knowledge, has not been previously reported, warrants further study. It is also worth mentioning that sex-related differences in carnitine pharmacokinetics have been described (27) . Specifically, females had higher levels of carnitine and acetylcarnitine following a single intravenous dose of acetylcarnitine (500 mg). In our study at T24, male carnitine-treated nonsurvivors (n ¼ 5) had a median (IQR) carnitine concentration of 626 (428-789) mM compared with females (n ¼ 4), who had a concentration of 1,250 (102-1,416) mM. Although the study of sex-related differences was not an objective of this work and it remains unclear whether sex influences sepsis survival (28) , evaluation of this biological variable will be important for deciphering carnitine-induced changes in the metabolome in future studies.
There are several important limitations to consider in this study. Most importantly, the sample size was limited by the original clinical trial. Nevertheless, given the highly significant differences between groups, broad and consistent trend in acylcarnitine levels, and biologic plausibility, we feel confident in the findings related to the impact of carnitine supplementation on acylcarnitine concentrations, though secondary analyses should be viewed as hypothesis generating. Second, detailed assessments of metabolic function, insulin sensitivity, and metabolic flexibility using methods such as carbon flux studies were not performed, so any conclusions regarding metabolic pathways and flexibility must be very guarded and rather serve as the impetus and rationale for future studies. Third, although it is possible that the observed changes led to improvements in energy balance and contributed to the observed improvement in clinical outcomes, due to measurements at individual time points in serum rather than tissue, and without the benefit of a flux analysis, we cannot definitely conclude what if any effects on energy metabolism carnitine treatment has on patients with septic shock, which would require follow-up studies. Finally, the patients enrolled in this clinical trial were all critically ill with a 28-day mortality in the placebo group approaching 60% and 1-year mortality of 75%. Patients demonstrated a significant vasopressor and organ failure requirement based on the study design, and therefore this cohort should not be considered representative of all patients with sepsis or even all those with septic shock, and generalization of these findings should be undertaken with caution.
CONCLUSIONS
In human patients with septic shock, L-carnitine supplementation induces a broad concentration range of acylcarnitines that persists after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome.
Nonsurvivors demonstrate a distinct metabolic response to L-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment. If these findings are confirmed and subsequently tested in clinical trials, the use of pretreatment metabolite levels to guide metabolic therapies would demonstrate a real-world application of pharmacometabolomics-driven precision medicine.
